ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed · Phase 3

Conditions studied: Paroxysmal Nocturnal Hemoglobinuria (PNH)

In brief

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).

Key facts

Study ID

NCT02946463

Run by

Alexion Pharmaceuticals, Inc.

People needed

272

Starts

2016-12-12

Expected to finish

2023-02-28

Last updated by the study team

2024-05-14

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Whittier, California, United States
• Research Site — Fort Worth, Texas, United States
• Research Site — Buenos Aires, Argentina
• Research Site — Buenos Aires, Argentina
• Research Site — Córdoba, Argentina
• Research Site — Perth, Australia
• Research Site — Linz, Austria
• Research Site — Vienna, Austria
• Research Site — Brussels, Belgium
• Research Site — Hasselt, Belgium
• Research Site — Leuven, Belgium
• Research Site — Rio de Janeiro, Brazil
• Research Site — Salvador, Brazil
• Research Site — São Paulo, Brazil
• Research Site — São Paulo, Brazil
• Research Site — Edmonton, Alberta, Canada
• Research Site — Toronto, Ontario, Canada
• Research Site — Pilsen, Czechia
• Research Site — Prague, Czechia
• Research Site — Tallinn, Estonia
• Research Site — Limoges, France
• Research Site — Montpellier, France
• Research Site — Paris, France
• Research Site — Pierre-Bénite, France
• Research Site — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.